At the 51st European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) Congress in Amsterdam, researchers presented new data from clinical trials supporting the long-term use of Soliris in patients living with aHUS.
Key findings of the data presented show that Soliris:
- substantially reduced the risk of mortality, compared to patients only receiving supportive care
- reversed kidney damage in aHUS patients who had received a kidney transplant, as well as patients with no transplant history
- enabled patients to discontinue dialysis and remain dialysis-free
The authors of one of the studies of Soliris concluded that recovery of kidney function was better in patients with their own kidneys, underscoring the importance of starting treatment with Soliris early to prevent progression to end-stage kidney disease and transplant.
To read the full press release: http://www.firstwordpharma.com/node/1214427?tsid=1#axzz33cGS3UPQ